Why is "Brigatinib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-22 15:31:44
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Brigatinib entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-22 and was most recently seen on 2026-06-22.
Wikipedia Overview
Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as an inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), as well as several nonreceptor tyrosine kinases such as FAK, FAK2, and FER. It shows activity against ALK-positive non–small cell lung cancer, ALK-positive anaplastic large cell lymphoma (ALCL), and NF2-related schwannomatosis.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Lung cancer drug offers a surprising new treatment against ovarian cancer - Mayo Clinic News Network
-
Respirology Case Reports | APSR Respiratory Medicine Journal - Wiley Online Library
-
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC - UT MD Anderson
-
BET proteins mediate survival mechanisms in human schwannoma model cells challenged with trametinib but not brigatinib | Oncogene - Nature
-
BRIGHTSTAR Evaluates Local Consolidative Therapy Plus Brigatinib for ALK-Rearranged NSCLC - Cancer Nursing Today
-
Mayo Clinic study finds lung cancer drug shows promise for ovarian cancer treatment - kttc.com
-
Lung Cancer Drug Tackles Ovarian Cancer Resistance - Inside Precision Medicine
-
Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors - The New England Journal of Medicine
-
Real-World NSCLC Case Study | Concurrent Uncommon EGFR Mutations & ALK Rearrangement Treated with... - Medical Dialogues
-
Mayo Clinic study reveals new ovarian cancer treatment hope - KIMT
-
Repurposing Brigatinib to Treat NF2-Related Schwannomatosis - The ASCO Post
-
Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma - Frontiers
-
Brigatinib decreases the size of NF2-related progressive tumors - 2 Minute Medicine
-
Cost-utility and budget impact analyses of anaplastic lymphoma kinase inhibitors in Thailand - Nature
-
Trials Highlight Changing Lung Cancer Treatment Landscape - National Cancer Institute (.gov)
-
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Sustained Complete Response to Brigatinib in a Young ALK+ NSCLC Patient - Medical Dialogues
-
Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin - The New England Journal of Medicine
-
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer - Nature
-
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer - Nature
-
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy Advisor
-
Insights into brigatinib’s rare side effects may help more lung cancer patients benefit from the drug - CU Anschutz newsroom
-
Game-Changer in Lung Cancer Treatment: NHS Approves Daily Pill That Could Save Lives - National Health Executive
-
FDA Grants Brigatinib Accelerated Approval for Metastatic Non-Small Cell Lung Cancer - National Cancer Institute (.gov)
-
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - MedPage Today
-
FDA Approves Brigatinib for Frontline ALK+ NSCLC - OncLive
-
Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025 - Cancer Therapy Advisor
-
Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement - Frontiers
-
Brigatinib for ALK -Positive Metastatic Non–Small Cell Lung Cancer - The ASCO Post
-
Brigatinib in Crizotinib-Pretreated Metastatic ALK-Positive Non–Small Cell Lung Cancer - The ASCO Post
-
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC - OncLive
-
CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News
-
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer - Nature
-
Dr. Rotow on Remaining Questions With Brigatinib in ALK+ NSCLC - OncLive
-
Brigatinib: First Global Approval - Springer Nature Link
-
Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells - Frontiers
-
Brigatinib Shows Clinical Benefit Across Multiple Tumor Types in Patients with NF2-Related Schwannomatosis with Progressive Tumors - Applied Clinical Trials Online
-
Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib - Frontiers
-
Second-Line Treatment for ALK-Positive NSCLC - OncLive
-
Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC) - Clinical Trials Arena
-
Brigatinib Receives Priority Review for First-Line Treatment of ALK+ Metastatic NSCLC - empr.com
-
Repurposed Drug Shrinks NF2-related Schwannomatosis Tumors - University of Miami
-
Brigatinib vs alectinib in crizotinib-refractory advanced ALK+ NSCLC by James Chih-Hsin Yang et al - Oncodaily
-
Selecting the Appropriate Treatment in ALK+ NSCLC - Targeted Oncology
-
Alunbrig (brigatinib) Cancer Medication - Cancer Health
-
Progression in ALK+ NSCLC After Frontline Therapy - OncLive
-
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types - MedPage Today
-
Next-generation ALK inhibitors: is the median the message? - The Lancet
-
Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer - PLOS
-
Choosing Between ALK Inhibitors in the Treatment of NSCLC - OncLive
-
Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC - OncLive
-
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori - Fierce Pharma
-
Takeda's Ariad deal pays off with blockbuster green light for Alunbrig - Fierce Pharma
-
Takeda’s Alunbrig available as primary therapy for lung cancer - koreabiomed.com
-
Takeda shells out whopping $5.2B for Ariad, Iclusig and its fledgling med brigatinib - Fierce Pharma
-
Takeda expects expanded insurance benefits for lung cancer drug in H1 - koreabiomed.com
-
#FierceMadness gets serious with 64 drug names, including play-in victors Taltz, Nerlynx - Fierce Pharma
-
New treatment option for Canadians with metastatic lung cancer - PR Newswire Canada
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.